Mestranol/hydroxyprogesterone acetate

{{Short description|Combination drug}}

{{Drugbox

| image = Mestranol.svg

| width = 250px

| caption =

| image2 = 17-Acetoxyprogesterone.svg

| width2 = 250px

| caption2 = Mestranol (top) and
hydroxyprogesterone acetate (bottom)

| type = combo

| drug_name = Mestranol /
hydroxyprogesterone acetate

| component1 = Mestranol

| class1 = Estrogen

| component2 = Hydroxyprogesterone acetate

| class2 = Progestogen

| tradename = Hormolidin

| Drugs.com =

| MedlinePlus =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category =

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| routes_of_administration = By mouth

| class = Estrogen; Progestogen

| CAS_number =

| ATC_prefix =

| ATC_suffix =

| PubChem =

| DrugBank =

| synonyms = ME/OHPA; EEME/OHPA

}}

Mestranol/hydroxyprogesterone acetate (ME/OHPA), sold under the brand name Hormolidin, is a combination medication of mestranol (ME), an estrogen, and hydroxyprogesterone acetate (OHPA), a progestin, which was reportedly used as a sequential combined birth control pill for women in the early 1970s.{{cite book | vauthors = Rudel HW, Kinel FA| chapter = Oral Contraceptives. Human Fertility Studies and Side Effects | pages = 385–469 | veditors = Tausk M | title = Pharmacology of the Endocrine System and Related Drugs: Progesterone, Progestational Drugs and Antifertility Agents | volume = II | url = https://books.google.com/books?id=Nv5sAAAAMAAJ | date = September 1972 | publisher = Pergamon Press | isbn = 978-0080168128 | oclc = 278011135}} It was formulated as oral tablets and contained 16 tablets of 80 μg ME, 5 tablets of 80 μg ME and 100 mg OHPA, and 7 placebo tablets (28 tablets in total). The medication was manufactured by the pharmaceutical company Gador in Argentina.